Ignis Therapeutics (Suzhou) Limited
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2022-06-28
- Employees
- -
- Market Cap
- -
A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)
Phase 3
Completed
- Conditions
- Sleep Apnea, ObstructiveExcessive Daytime Sleepiness
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Ignis Therapeutics (Suzhou) Limited
- Target Recruit Count
- 204
- Registration Number
- NCT06103825
- Locations
- 🇨🇳
West China fourth Hospital Sichuan University, Sichuan, China
🇨🇳ShenZhen People's Hospital, Shenzhen, China
🇨🇳Shanghai Sixth People's Hospital, ShangHai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath